Evaxion announces successful completion of the initial phases of ongoing vaccine collaboration with msd

Copenhagen, denmark, feb. 20, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) ("evaxion" or the "company"), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with msd (tradename of merck & co., inc., rahway, nj, usa). the vaccine development project combines both organizations' unique capabilities and know-how.
EVAX Ratings Summary
EVAX Quant Ranking